MX2020003193A - Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos. - Google Patents

Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.

Info

Publication number
MX2020003193A
MX2020003193A MX2020003193A MX2020003193A MX2020003193A MX 2020003193 A MX2020003193 A MX 2020003193A MX 2020003193 A MX2020003193 A MX 2020003193A MX 2020003193 A MX2020003193 A MX 2020003193A MX 2020003193 A MX2020003193 A MX 2020003193A
Authority
MX
Mexico
Prior art keywords
recombinant antibodies
analytical purposes
bispecific recombinant
multivalent
mono
Prior art date
Application number
MX2020003193A
Other languages
English (en)
Inventor
Tobias Oelschlaegel
Pavel Kubalec
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020003193A publication Critical patent/MX2020003193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Reproductive Health (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente descripción se refiere a nuevos anticuerpos recombinantes multivalentes específicos de analito que son particularmente útiles en inmunoensayos. Específicamente se describen anticuerpos hexavalentes, octavalentes y decavalentes, su construcción, producción, caracterización y uso en ensayos de detección de antígeno objetivo.
MX2020003193A 2017-09-22 2018-09-20 Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos. MX2020003193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192532 2017-09-22
PCT/EP2018/075464 WO2019057816A1 (en) 2017-09-22 2018-09-20 MULOMALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTICAL PURPOSES

Publications (1)

Publication Number Publication Date
MX2020003193A true MX2020003193A (es) 2020-07-29

Family

ID=59930280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003193A MX2020003193A (es) 2017-09-22 2018-09-20 Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.

Country Status (11)

Country Link
US (1) US20210017272A1 (es)
EP (1) EP3684801A1 (es)
JP (3) JP7432502B2 (es)
KR (1) KR20200053581A (es)
CN (1) CN111133001B (es)
AU (1) AU2018335231B2 (es)
BR (1) BR112020005737A2 (es)
CA (1) CA3075450A1 (es)
MX (1) MX2020003193A (es)
WO (1) WO2019057816A1 (es)
ZA (1) ZA202001298B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020229378A1 (en) * 2019-05-13 2020-11-19 F. Hoffmann-La Roche Ag Interference-suppressed pharmacokinetic immunoassay
US10994021B1 (en) * 2020-04-11 2021-05-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Tetravalent antibody-drug conjugates and use thereof
CN112239505B (zh) * 2020-10-13 2022-05-20 上海良润生物医药科技有限公司 重组抗cd171八价抗体及神经来源外泌体的捕获方法
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体
EP4201430A1 (en) 2021-12-23 2023-06-28 F. Hoffmann-La Roche AG Modified antibody for site-specific conjugation and its diagnostic use
CN119213025A (zh) 2022-05-16 2024-12-27 豪夫迈·罗氏有限公司 与α-1,6-核心-岩藻糖基化的甲胎蛋白特异性结合的高亲和力抗体
EP4695308A1 (en) * 2023-09-14 2026-02-18 Invitrogen BioServices India Private Limited Engineered antibodies and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GR850899B (es) * 1984-04-12 1985-11-25 Gen Hospital Corp
US4657853A (en) 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
ATE91024T1 (de) * 1986-12-04 1993-07-15 David Michael Kemeny Festphasenimmunoassayverfahren.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11326324A (ja) 1998-05-07 1999-11-26 Matsushita Electric Ind Co Ltd 間接重合標識抗体およびその製造方法
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO2001077182A1 (en) 2000-04-07 2001-10-18 Matsushita Electric Industrial Co., Ltd. Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2007254004A1 (en) * 2006-02-02 2007-11-29 The General Hospital Corporation Engineered antibody-stress protein fusions
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
CN102851369B (zh) * 2006-12-13 2015-01-21 卢米耐克斯公司 用于实时pcr多重分析的系统和方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
SG175077A1 (en) * 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US20110008766A1 (en) * 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
RU2014121043A (ru) * 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US9767555B2 (en) * 2015-01-05 2017-09-19 Case Western Reserve University Disease characterization from fused pathology and radiology data
WO2016146702A1 (en) * 2015-03-16 2016-09-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Trispecific binding molecules for treating hbv infection and associated conditions
AU2016334623A1 (en) * 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor

Also Published As

Publication number Publication date
JP2024026215A (ja) 2024-02-28
AU2018335231B2 (en) 2022-03-24
JP2022133350A (ja) 2022-09-13
WO2019057816A1 (en) 2019-03-28
EP3684801A1 (en) 2020-07-29
CA3075450A1 (en) 2019-03-28
CN111133001A (zh) 2020-05-08
CN111133001B (zh) 2024-02-06
RU2020113387A3 (es) 2021-10-22
JP7432502B2 (ja) 2024-02-16
JP2020534309A (ja) 2020-11-26
ZA202001298B (en) 2025-04-30
AU2018335231A1 (en) 2020-03-19
BR112020005737A2 (pt) 2020-11-17
KR20200053581A (ko) 2020-05-18
US20210017272A1 (en) 2021-01-21
RU2020113387A (ru) 2021-10-22
JP7685036B2 (ja) 2025-05-28

Similar Documents

Publication Publication Date Title
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
MX377772B (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
MX374976B (es) Anticuerpos y metodos de uso.
CR20170251A (es) Anticuerpos anti-c5 y métodos para su uso
BR112014025830A8 (pt) Polipeptídeos de ligação ao cd3
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
BR112015023239A8 (pt) ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
MX2018016096A (es) Anticuerpos antagonistas de anti-axl.
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
EP3459973A4 (en) Anti-human pd-l1 humanized monoclonal antibody and application thereof
MX2016007887A (es) Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
MX2018004763A (es) Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
WO2014144725A3 (en) Melatonin monoclonal antibody, detection, methods and uses thereof
CO2023004251A2 (es) Anticuerpo que se une a vegf-a y ang2, y métodos de uso